RenataDHA:RENATA +0.27%83 EBITDA Margin % is 16.14% as of Mar. 2026, which is 34% below its 10-year median of 24.45. GuruFocus rates DHA:RENATA with a GF Score™ of 83/100 and a GF Value™ of BDT806.73 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, Renata ranks better than 56.02% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Renata's EBITDA for the
three
months ended in Mar. 2026 was BDT1,837 Mil. Renata's Revenue for the
three
months ended in Mar. 2026 was BDT11,381 Mil. Therefore, Renata's EBITDA margin for the quarter that ended in Mar. 2026 was 16.14%.
Renata (DHA:RENATA) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Renata EBITDA Margin % Related Terms
Renata EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Renata's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:RENATA vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Renata's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renata EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renata's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Renata's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renata (DHA:RENATA) has a EBITDA Margin % of 16.14% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Renata and its competitors. This is 34% below median its historical median of 24.45. Over the past decade, Renata's EBITDA Margin % has ranged from 13.31 to 28.31. According to the industry distribution chart, Renata ranks #420 out of 955 companies in the Drug Manufacturers industry, placing it in the top 44%.
Is Renata's EBITDA Margin % too high?
Renata's current EBITDA Margin % of 16.14% is 34% below median its 10-year median of 24.45. Over the past 10 years, this metric has ranged from a low of 13.31 to a high of 28.31. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Renata's value of 16.14% is 29.7% above this industry median. Based on the distribution chart, Renata ranks #420 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Renata has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Renata ranks #420 out of 955 companies for EBITDA Margin %. This puts Renata in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Renata's value of 16.14% is 29.7% above this benchmark. Historically, Renata's own EBITDA Margin % has ranged from 13.31 to 28.31 over the past decade. While the company's 10-year median is 24.45 vs. the industry median of 12.44, Renata has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renata's current EBITDA Margin % of 16.14% is 29.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Renata and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renata's current EBITDA Margin % is 16.14%, which is 34% below median its own 10-year median of 24.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT806.73, compared to a current price of BDT446.30 — trading 44.7% below its estimated fair value. The current EBITDA Margin % is 16.14%, which is 34% below median its 10-year median of 24.45 and 29.7% above the Drug Manufacturers industry median of 12.44. Renata's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Renata (DHA:RENATA), the current EBITDA Margin % is 16.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renata (DHA:RENATA) Overvalued in 2026?
Based on GuruFocus' analysis, Renata stock appears to be undervalued.
The current stock price of BDT446.30 is trading 44.7% below its estimated GF Value™ of BDT806.73.
GuruFocus considers Renata to be Significantly Undervalued.
Key valuation signals for DHA:RENATA:
EBITDA Margin %: 16.14% (34% below median its 10-year median of 24.45)
GF Value™: BDT806.73 vs. price of BDT446.30 (44.7% below fair value)
Industry Position: 29.7% above the Drug Manufacturers median (#420 of 955)
No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
83GF Score
Get the complete analysis for DHA:RENATA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:RENATA has been successfully added to your 
